Flavone Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

A recruiting clinical trial sponsored by an academic medical institution, University Hospital Rijeka, is evaluating the therapeutic potential of flavone interventions in patients with stage IV and metastatic melanoma. Operating under a trial phase designated as Not Applicable, this study investigates gut microbiome alterations, patient quality of life, and radiological responses in advanced skin cancer. Overall, the current clinical landscape for flavone remains focused on these specialized supportive care regimes.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06236360	Recruiting	Melanoma Stage Iv\|Metastatic Melanoma	University Hospital Rijeka	2023-12-21	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Flavone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Flavone modulates cellular enzymatic activities and pro-survival signaling targets, thereby inhibiting downstream oxidative stress pathways and suppressing uncontrolled cellular proliferation. By inducing apoptotic cascades and disrupting oncogenic signal transduction, this compound provides mechanistically relevant anti-tumor effects against progressive stage IV metastatic melanoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).